In an effort to smooth approval for its $106 billion merger, Pfizer and AstraZeneca are set to meet UK regulators on Tuesday who are wary a deal will lead to British job cuts. For its part, Pfizer says it has already made legally binding commitments with the UK government which include maintaining 20% of the company's R&D facilities in the U.K. and pledging to establish the combined company's corporate and tax residence in the UK. Warwick Business School's Hossam Zeitoun says that any promises Pfizer makes to the UK can easily be reversed if conditions change. Ruben Ramirez reports.

More from Video

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

3M's Chief Science Advocate on Advancing Healthcare, Autos and Young Scientists

3M's Chief Science Advocate on Advancing Healthcare, Autos and Young Scientists

Listen: Should You Buy Cisco Now?

Listen: Should You Buy Cisco Now?

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

It's Dumb to Think There Aren't Already Monopolies in Big Tech

It's Dumb to Think There Aren't Already Monopolies in Big Tech